Floatz logo

Saponin-Based Immunoadjuvant Obi-821

Metastatic Lung Cancer

OBI Pharma, IncmixturePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

304 Active assets in the Metastatic Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

Saponin-Based Immunoadjuvant Obi-821 is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
breast cancerDormant
B
Indicative ·
58 / 100
View asset →
fallopian tube cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →